Several members of the Alliance wrote to Senate Finance Committee Chairman Grassley (R-IA) and Ranking Member Wyden (D-OR), expressing concern about a reimbursement cap on the Average Sales Price (ASP) add-on proposed in the Prescription Drug Pricing Reduction Act (S.2543). The letter points out that reducing physician reimbursement for acquiring, storing, handling, and administering Part B drugs will do nothing to reduce the prices of the underlying products. Additionally, reductions in the ASP add-on disproportionately harm small and rural practices, who already experience difficulty acquiring medicines at ASP.

Letter to Senate Finance Committee on Section 109 of S.2543

The Alliance Staff

Author The Alliance Staff

More posts by The Alliance Staff

Leave a Reply